pravastatin has been researched along with valsartan in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Amano, N; Maeda, K; Moriwaki, T; Nakakariya, M; Ono, M; Sugiyama, Y | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Grime, K; Paine, SW | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujino, A; Fujiwara, H; Hirano, M; Ieiri, I; Kitamura, Y; Kusuhara, H; Maeda, K; Otsubo, K; Sugiyama, Y; Watanabe, T; Yasuda, K | 1 |
| Fujimoto, M; Hashimoto, N; Imamura, H; Nakazawa, K; Ohta, T | 1 |
| Galetin, A; Houston, JB; Kenworthy, KE; Ménochet, K | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Apola, A; Kwiecień, A; Maślanka, A; Opoka, W; Stolarczyk, M | 1 |
2 review(s) available for pravastatin and valsartan
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for pravastatin and valsartan
| Article | Year |
|---|---|
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Topics: Adult; Animals; Antihypertensive Agents; Area Under Curve; Cells, Cultured; Cross-Over Studies; Dogs; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Tetrazoles; Thiazepines; Valine; Valsartan | 2006 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
14 other study(ies) available for pravastatin and valsartan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Lactams; Biliary Tract; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Topotecan | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Body Weight; Dogs; Drug Administration Routes; Humans; Liver; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Pharmaceutical Preparations; Protein Binding; Rats; Species Specificity | 2013 |
[Case report of cholesterol crystal embolism 1 month after carotid stenting].
Topics: Aged; Angioplasty, Balloon, Coronary; Carotid Stenosis; Drug Therapy, Combination; Early Diagnosis; Embolism, Cholesterol; Humans; Male; Pravastatin; Prednisolone; Stents; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2007 |
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Transport; Bosentan; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Models, Biological; Organic Anion Transporters; Piperidines; Pravastatin; Pyrimidines; Quinolines; Rats; Rosuvastatin Calcium; Species Specificity; Sulfonamides; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry; Valsartan | 2017 |